Sitagliptin + Dapagliflozin Tablets

Therapeutic Indication

Type 2 Diabetes Mellitus (T2DM)

Improves glycemic control when diet and exercise alone are insufficient

Combination therapy for patients requiring dual mechanism of action

Cardiovascular and renal protective benefits

+91 85919 78885

Sitagliptin + Dapagliflozin

Tablet

Sitagliptin is a DPP-4 inhibitor that enhances incretin activity, increasing insulin release and decreasing glucagon levels. Dapagliflozin is an SGLT2 inhibitor that lowers blood glucose by promoting urinary glucose excretion. Together, they provide complementary mechanisms for effective glycemic control, weight management, and cardiovascular protection in type 2 diabetes patients.

Speciality	DPP-4 Inhibitor + SGLT2 Inhibitor Combination
Tags	Diabetes \| Combination Therapy \| Blood Sugar Control
Strength	Sitagliptin 100 mg Dapagliflozin 5mg/10 mg
Packing Size	10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Sitagliptin inhibits DPP-4, prolonging incretin activity to stimulate insulin secretion and suppress glucagon. Dapagliflozin inhibits SGLT2 in renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. The dual mechanism provides synergistic glycemic control.

Pharmacokinetics

Sitagliptin Absorption: Rapid oral absorption
Sitagliptin Elimination: Primarily renal
Dapagliflozin Metabolism: Hepatic via CYP3A4
Dapagliflozin Half-life: 12–13 hours

Side Effects

Urinary tract infections
Genital mycotic infections
Nasopharyngitis
Hypoglycemia (with insulin or sulfonylureas)

Contraindication

Severe renal impairment
Hypersensitivity to Sitagliptin or Dapagliflozin

Interaction

Diuretics (risk of dehydration)
Insulin or sulfonylureas (risk of hypoglycemia)

Warning and Precautions

Monitor renal function regularly
Ensure adequate hydration
Use cautiously in elderly patients